Reuters logo
BRIEF-Ipsen announces success of phase 3 CELESTIAL trial of Cabozantinib
2017年10月16日 / 上午11点07分 / 1 个月前

BRIEF-Ipsen announces success of phase 3 CELESTIAL trial of Cabozantinib

Oct 16 (Reuters) - IPSEN SA:

* IPSEN ANNOUNCES THAT PHASE 3 CELESTIAL TRIAL OF CABOZANTINIB MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

* ‍IPSEN EXPECTS TO FILE IN H1 2018 A VARIATION OF INITIAL APPLICATION TO EMA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below